ATP binding cassette transporters and drug resistance in breast cancer

Endocrine-Related Cancer

Volumn 10, Issue 1, 2003, Pages 43-73

  Leonessa, F ^a   Clarke, R ^b,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; ABC TRANSPORTER; ALKALOID DERIVATIVE; ANTHRACYCLINE DERIVATIVE; BEPRIDIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GESTAGEN; GLYCOPROTEIN P; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PREDNISONE; QUININE; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; TECHNETIUM 99M; TESTOSTERONE; TETROFOSMIN TC 99M; TRIFLUOPERAZINE; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; BREAST CARCINOMA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFECT; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 0037362355     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100043     Document Type: Review

References (239)

1. Abraham I, Wolf CL & Sampson KE 1993 Non-glucocorticoid steroid analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine. Cancer Chemotherapy and Pharmacology 32 116-122.
2. Alabaster O, Woods T, Ortiz-Sanchez V & Jahangeer S 1989 Influence of microenvironmental pH on adriamycin resistance. Cancer Research 49 5638-5643.
3. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V & Dean M 1998 A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Research 58 5337-5339.
4. 99mTc-sestamibi for palpable breast lesions. Journal of Nuclear Medicine 43 882-888.
5. Arnal M, Franco N, Fargeot P, Riedinger JM, Brunet-Lecomte P & Lizard-Nacol S 2000 Enhancement of MDR1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Research and Treatment 61 13-20.
6. Ballinger JR, Hua HA, Berry BW, Firby P & Boxen I 1995 99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nuclear Medicine Communications 16 253-257.
7. Barbarics E, Kronauge JF, Cohen D, Davison A, Jones AG & Croop JM 1998 Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Research 58 276-282.
8. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B et al. 1997 Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nature Medicine 3 447-450.
9. Barnes KM, Dickstein B, Cutler GB Jr, Fojo T & Bates SE 1996 Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 35 4820-4827.
10. Bates SE, Meadows B, Goldspiel BR, Denicoff A, Le TB, Tucker E, Steinberg SM & Elwood LJ 1995 A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. Cancer Chemotherapy and Pharmacology 35 457-463.
11. Beck J, Bohnet B, Brugger D, Bader P, Dietl J, Scheper RJ, Kandolf R, Liu C, Niethammer D & Gekeler V 1998 Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression. British Journal of Cancer 77 87-91.
12. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM et al. 1996 Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Research 56 3010-3020.
13. Bellamy WT 1996 P-glycoproteins and multidrug resistance. Annual Review of Pharmacology and Toxicology 36 161-183.
14. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier M-J, Krakowski I, Netter-Pinon G, Frenay M, Gousset C, Mari FN et al. 2000 Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Annals of Oncology 11 1471-1476.
15. Berghammer P, Obwegeser R, Müllauer-Ertl S, Karanikas G, Wiltschke C, Kubista E, Sinzinger H & Zielinski C 1999 99m-Tc-tetrofosmin scintigraphy and breast cancer. Gynecologic Oncology 73 87-90.
16. Biedler JL & Riehm H 1970 Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Research 30 1174-1184.
17. Binaschi M, Supino R, Gambetta RA, Giaccone G, Prosperi E, Capranico G, Cataldo I & Zunino F 1995 MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. International Journal of Cancer 62 84-89.
18. Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E et al. 1997 A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. Seminars in Oncology 24 S17.
19. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H et al. 1999 Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. Journal of Clinical Oncology 17 2355-2364.
20. Bodey B, Bodey B Jr, Groger AM, Luck JV, Siegel SE, Taylor CR & Kaiser HE 1997 Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance. Anticancer Research 17 1311-1318.
21. Bonadonna G, Valagussa P, Brambilla C, Moliterni A, Zambetti M & Ferrari L 1991 Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy. Seminars in Oncology 18 515-524.
22. Borst P, Evers R, Kool M & Wijnholds J 1999 The multidrug resistance protein family. Biochimica et Biophysica Acta 1461 347-357.
23. Borst P, Evers R, Kool M & Wijnholds J 2000 A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute 92 1295-1302.
24. Botti G, Chiappetta G, D'Aiuto G, de Angelis E, De Matteis A, Montella M, Picone A & Cascione F 1993 PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study. Tumori 79 214-218.
25. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, Di Marco B, Aguggini S, Bolsi G, Cirillo F et al. 2000 p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clinical Cancer Research 6 2751-2758.
26. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA & Kruh GD 1995 Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Research 55 5342-5347.
27. Brotherick I, Shenton BK, Egan M, Cunliffe WE, Browell DA, Lunt LG, Young JR & Higgs MJ 1996 Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometry. European Journal of Cancer 32A 2334-2341.
28. Buser K, Joncourt F, Altermatt HJ, Bacchi M, Oberli A & Cerny T 1997 Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Annals of Oncology 8 335-341.
29. Callaghan R & Higgins CF 1995 Interaction of tamoxifen with the multidrug resistance P-glycoprotein. British Journal of Cancer 71 294-299.
30. Caner B, Kitapci M, Aras T, Erbengi G, Ugur O & Bekdik C 1991 Increased accumulation of hexakis (2-methoxyisobutylisonitrile)-technetium(I) in osteosarcoma and its metastatic lymph nodes. Journal of Nuclear Medicine 32 1977-1978.
31. 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. International Journal of Oncology 20 1049-1055.
32. Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C, Horschowski N & Piana L 1994 Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. Journal of the National Cancer Institute 86 1539-1545.
33. Chaudhary PM & Roninson IB 1991 Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66 85-94.
34. Chaudhary PM & Roninson IB 1993 Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. Journal of the National Cancer Institute 85 632-639.
35. Chaudhary PM, Mechetner EB & Roninson IB 1992 Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80 2735-2739.
36. Chen WS, Luker KE, Dahlheimer JL, Pica CM, Luker GD & Piwnica-Worms D 2000 Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochemical Pharmacology 60 413-426.
37. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H & Vielh P 1996 Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77 292-300.
38. Chevillard S, Lebeau J, Pouillart P, de Toma C, Beldjord C, Asselain B, Klijanienko J, Fourquet A, Magdelenat H & Vielh P 1997 Biological and clinical significance of concurrent p53 gene alteralions, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clinical Cancer Research 3 2471-2478.
39. Childs S, Yeh RL, Hui D & Ling V 1998 Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Research 58 4160-4167.
40. Chin KV, Tanaka S, Darlington G, Pastan I & Gottesman MM 1990 Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. Journal of Biological Chemistry 265 221-226.
41. Chung HC, Rha SY, Kim JH, Roh JK, Min JS, Lee KS, Kim BS & Lee KB 1997 P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Research and Treatment 42 65-72.
42. Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV, Thomas R, Botti G, D'Aiuto G & Salvatore M 1998 Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Clinical Oncology 16 1677-1683.
43. Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM & Dickson RB 1992 Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. Journal of the National Cancer Institute 84 1506-1512.
44. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV & Deeley RG 1992 Science 258 1650-1654.
45. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM & Deeley RG 1994 Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Research 54 5902-5910.
46. Coley HM, Amos WB, Twentyman PR & Workman P 1993 Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. British Journal of Cancer 67 1316-1323.
47. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR & Bertino JR 1989 Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. PNAS 86 695-698.
48. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR & Melamed MR 1990 Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. Journal of Histochemistry and Cytochemistry 38 1277-1287.
49. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P & Housman DE 1989 The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Molecular and Cellular Biology 9 1346-1350.
50. Dano K 1972 Cross resistance between vinca alkaloids and anthracyclines in Erlich ascites tumor in vivo. Cancer Chemotherapy Reports 56 701-708.
51. Dano K 1973 Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochimica et Biophysica Acta 323 466-483.
52. Daoud R, Julien M, Gros P & Georges E 2001 Major photoaffinity drug binding sites in multidrug resistance protein 1 (MRP1) are within transmembrane domains 10-11 and 16-17. Journal of Biological Chemistry 276 12324-12330.
53. Davey MW, Hargrave RM & Davey RA 1996 Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells. Leukemia Research 20 657-664.
54. Dean M, Rzhetsky A & Allikmets R 2001 The human ATP-binding cassette (ABC) transporter superfamily. Genome Research 11 1156-1166.
55. De Boer AG, van der Sandt ICJ & Gaillard PJ 2003 The role of drug transporters at the blood-brain barrier. Annual Review of Pharmacology and Toxicology 43 629-656.
56. Decker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL & Farkas DH 1995 Immunohistochemical analysis of P-glycoprotein expression in breast cancer: clinical correlations. Annals of Clinical and Laboratory Science 25 52-59.
57. De la Torre TM, Larsson R, Nygren P, Lindgren A & Bergh J 1994 Expression of the multidrug-resistance gene product in untreated human breast cancer and its relationship to prognostic markers. Acta Oncologica 33 773-777.
58. Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, Thomas R, D'Aiuto G, Tsuruo T & Salvatore M 1997 Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. Journal of Nuclear Medicine 38 1348-1351.
59. Desoize B & Jardillier J 2000 Multicellular resistance: a paradigm for clinical resistance? Critical Reviews in Oncology/Hematology 36 193-207.
60. Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogakto A, Leighton JC & Goldstein LJ 1998 Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clinical Cancer Research 4 1533-1542.
61. Dixon AR, Bell J, Ellis IO, Elston CW & Blamey RW 1992 P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy. British Journal of Cancer 66 537-541.
62. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK & Ross DD 1998 A multidrug resistance transporter from human MCF-7 breast cancer cells. PNAS 95 15665-15670.
63. Early Breast Cancer Trialists' Collaborative Group 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 930-942.
64. Elledge RM & Allred DC 1998 Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Research and Treatment 52 79-98.
65. Ellis MJ, Hayes DF & Lippman ME 2000 Treatment of metastatic breast cancer. In Diseases of the Breast, pp 749-797. Eds JR Harris, ME Lippman, M Morrow & CK Osborne. Philadelphia: Lippincott-Raven.
66. Evers R, Cnubben NH, Wijnholds J, van Deemter L, van Bladeren PJ & Borst P 1997 Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Letters 419 112-116.
67. Fairchild CR & Cowan KH 1991 Keynote address: multidrug resistance: a pleiotropic response to cytotoxic drugs. International Journal of Radiation Oncology, Biology, Physics 20 361-367.
68. Faneyte IF, Kristel PM, van de Vijver MJ 2001 Determining MDR1/P-glycoprotein expression in breast cancer. International Journal of Cancer 93 114-122.
69. Ferrero JM, Etienne MC, Formento JL, Francoual M, Rostagno P, Peyrottes I, Ettore F, Teissier E, Leblanc-Talent P, Namer M et al. 2000 Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients. British Journal of Cancer 82 171-177.
70. Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D & Pirker R 1996 MRP and MDR1 gene expression in primary breast carcinomas. Clinical Cancer Research 2 1231-1237.
71. Filipits M, Malayeri R, Suchomel RW, Pohl G, Stranzl T, Dekan G, Kaider A, Stiglbauer W, Depisch D & Pirker R 1999 Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Research 19 5043-5049.
72. Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D & Vickers AE 1998 The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metabolism and Disposition 26 802-811.
73. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM & Pastan I 1987 Expression of a multidrug-resistance gene in human tumors and tissues. PNAS 84 265-269.
74. Gago FE, Tello OM, Diblasi AM & Ciocca DR 1998 Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 67 431-437.
75. Germann UA, Ford PJ, Shlyakhter D, Mason VS & Harding MW 1997 Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8 141-155.
76. Goldsmith ME, Gudas JM, Schneider E & Cowan KH 1995 Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. Journal of Biological Chemistry 270 1894-1898.
77. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM et al. 1989 Expression of a multidrug resistance gene in human cancers. Journal of the National Cancer Institute 81 116-124.
78. Gottesman MM 2002 Mechanisms of cancer drug resistance. Annual Review of Medicine 53 615-627.
79. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK & Buzdar AU 1996 Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. Journal of Clinical Oncology 14 2197-2205.
80. Gregorcyk S, Kang Y, Brandt D, Kolm P, Singer G & Perry RR 1996 p-Glycoprotein expression as a predictor of breast cancer recurrence. Annals of Surgical Oncology 3 8-14.
81. Gros P, Croop J & Housman D 1986 Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47 371-380.
82. Gruol DJ & Bourgeois S 1994 Expression of the mdrl P-glycoprotein gene: a mechanism of escape from glucocorticoid-induced apoptosis. Biochemistry and Cell Biology 72 561-571.
83. Gruol DJ & Bourgeois S 1997 Chemosensitizing steroids: glucocorticoid receptor agonists capable of inhibiting P-glycoprotein function. Cancer Research 57 720-727.
84. Gruol DJ, Zee MC, Trotter J & Bourgeois S 1994 Reversal of multidrug resistance by RU 486. Cancer Research 54 3088-3091.
85. Harris JW, Rahman A, Kim BR, Guengerich FP & Collins JM 1994 Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Research 54 4026-4035.
86. Hassan IM, Sahweil A, Constantinides C, Mahmoud A, Nair M, Omar YT & Abdel-Dayem HM 1989 Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clinical Nuclear Medicine 14 333-340.
87. He L, Hao C, Lin B, Wang Y & Gao F 1995 P-glycoprotein expression in primary breast cancer. Chinese Medical Sciences Journal 10 12-15.
88. Hegewisch-Becker S, Staib F, Loning T, Pichlmeier U, Kroger N, Reymann A & Hossfeld DK 1998 No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer. Annals of Oncology 9 85-93.
89. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV & Lankelma J 1997 Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochimica et Biophysica Acta 1326 12-22.
90. Henderson IC 1987 Chemotherapy for advanced disease. In Breast Diseases, pp 428-479. Eds JR Harris, S Hellman, IC Henderson & DW Kinne. Philadelphia: JB Lippincott.
91. Hendrikse NH, Franssen EJ, van der Graaf WT, Meijer C, Piers DA, Vaalburg W & de Vries EG 1998 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. British Journal of Cancer 77 353-358.
92. Hendrikse NH, Franssen EJ, van der Graaf WT, Vaalburg W & de Vries EG 1999 Visualization of multidrug resistance in vivo. European Journal of Nuclear Medicine 26 283-293.
93. Hennequin E, Delvincourt C, Poumy C & Jardillier JC 1993 Expression of mdrl gene in human breast primary tumors and metastases. Breast Cancer Research and Treatment 26 267-274.
94. Higgins CF & Gottesman MM 1992 Is the multidrug transporter a flippase? Trends in Biochemical Sciences 17 18-21.
95. Holmes JA, Jacobs A, Carter G, Whittaker JA, Bentley DP & Padua RA 1990 Is the mdr 1 gene relevant in chronic lymphocytic leukemia? Leukemia 4 216-218.
96. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J & Pinedo HM 1998 Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. British Journal of Cancer 77 621-626.
97. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM & Jansen G 1999 Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Research 59 2532-2535.
98. Hu XF, Nadalin G, De Luise M, Martin TJ, Wakeling A, Huggins R & Zalcberg JR 1991 Circumvention of doxorubicin resistance in multi-drug resistant human leukaemia and lung cancer cells by the pure antioestrogen ICI 164384. European Journal of Cancer 27 773-777.
99. Hu XF, Slater A, Kantharidis P, Rischin D, Juneja S, Rossi R, Lee G, Parkin JD & Zalcberg JR 1999 Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 93 4086-4095.
100. Hu Z, Jin S & Scotto KW 2000 Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. Journal of Biological Chemistry 275 2979-2985.
101. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD & Kuo MT 1996 Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. Journal of Biological Chemistry 271 14981-14988.
102. Ito K, Fujimori M, Nakata S, Hama Y, Shingu K, Kobayashi S, Tsuchiya S, Kohno K, Kuwano M & Amano J 1998 Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. Oncology Research 10 99-109.
103. Ito K, Olsen SL, Qiu W, Deeley RG & Cole SP 2001 Mutation of a single conserved tryptophan in multidrug resistance protein 1(MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. Journal of Biological Chemistry 276 15616-15624.
104. Izquierdo MA, Neefjes JJ, Mathari AE, Flens MJ, Scheffer GL & Scheper RJ 1996 Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. British Journal of Cancer 74 1961-1967.
105. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G & Keppler D 1996 Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Research 56 988-994.
106. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B & Keppler D 1997 ATP-dependent transport of bilirubin glucuronides by the multidrug resistance MRP1 and its hepatocyte canalicular isoform MRP2. Biochemical Journal 327 305-310.
107. Juliano RL & Ling V 1976 A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 455 152-162.
108. Kacinski BM, Yee LD, Carter D, Li D & Kuo MT 1989 Human breast carcinoma cell levels of MDR1 (P-glycoprotein) transcripts correlate in vivo inversely and reciprocally with tumor progesterone receptor content. Cancer Communications 1 1-6.
109. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M & Takebayashi Y 2001 Expression of multidrug resistance-related transporters in human breast carcinoma. Japanese Journal of Cancer Research 92 452-458.
110. Kao CH, Tsai SC, Liu TJ, Ho YJ, Wang JJ, Ho ST & Chang Lai SP 2001 P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Research 61 1412-1414.
111. Kasimir-Bauer S, Ottinger H, Meusers P, Beelen DW, Brittinger G, Seeber S & Scheulen ME 1998 In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Experimental Hematology 26 1111-1117.
112. Keen JC, Miller EP, Bellamy C, Dixon JM & Miller WR 1994 P-glycoprotein and resistance to tamoxifen. Lancet 343 1047-1048.
113. Keith WN Stallard S & Brown R 1990 Expression of mdrl and gst-pi in human breast tumours: comparison to in vitro chemosensitivity. British Journal of Cancer 61 712-716.
114. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM et al. 1999 Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical Research 16 408-414.
115. Klein I, Sarkadi B & Varadi A 1999 An inventory of the human ABC proteins. Biochimica et Biophysica Acta 1461 237-262.
116. Klimecki WT, Futscher BW, Grogan TM & Dalton WS 1994 P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83 2451-2458.
117. Kling KM, Ostrzega N & Schmit P 1997 Breast conservation after induction chemotherapy for locally advanced breast cancer. American Surgeon 63 861-864.
118. Koh EH, Chung HC, Lee KB, Lim HY, Kim JH, Roh JK, Min JS, Lee KS & Kim BS 1992 The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. Yonsei Medical Journal 33 137-142.
119. Kostakoglu L, Elahi N, Kiratli P, Ruacan S, Sayek I, Baltali E, Sungur A, Hayran M & Bekdik CF 1997 Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. Journal of Nuclear Medicine 38 1003-1008.
120. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergun EL & Bekdik CF 1998 Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. Journal of Nuclear Medicine 39 228-234.
121. Lacave R, Coulet F, Ricci S, Touboul E, Flahault A, Rateau JG, Cesari D, Lefranc JP & Bemaudin JF 1998 Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas. British Journal of Cancer 77 694-702.
122. Lankat-Buttgereit B & Tampe R 1999 The transporter associated with antigen processing TAP: structure and function. FEBS Letters 464 108-112.
123. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB & Schuetz JD 2000 Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Molecular Pharmacology 57 24-35.
124. Lehne G, Elonen E, Baekelandt M, Skovsgaard T & Peterson C 1997 Challenging drug resistance in cancer therapy - review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9th and 10th, 1997. Acta Oncologica 37 431-439.
125. Lehnert M, Mross K, Schueller J, Thuerlimann B, Kroeger N & Kupper H 1998 Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. British Journal of Cancer 77 1155-1163.
126. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG & Keppler D 1994 The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. Journal of Biological Chemistry 269 27807-27810.
127. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M & Clarke R 1994 Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170 000 glycoprotein (gp170) binding studies. Cancer Research 54 441-447.
128. Leonessa F, Kim J-H, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A & Clarke R 2002 C-7 analogs of progesterone as potent inhibitors of the P-glycoprotein efflux pump. Journal of Medicinal Chemistry 45 390-398.
129. Li ZH, Zhu YJ & Lit XT 1997 Wild-type p53 gene increases MDR1 gene expression but decreases drug resistance in an MDR cell line KBV200. Cancer Letters 119 177-184.
130. Ling V & Thompson LH 1974 Reduced permeability in CHO cells as a mechanism of resistance to colchicine. Journal of Cellular Physiology 83 103-116.
131. Linn SC, Giaccone G, van Diest PJ, Blokhuis WM, van der Valk P, van Kalken CK, Kuiper CM, Pinedo HM & Baak JP 1995 Prognostic relevance of P-glycoprotein expression in breast cancer. Annals of Oncology 6 679-685.
132. Linn SC, Honkoop AH, Hoekman K, van d, V, Pinedo HM & Giaccone G 1996 p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. British Journal of Cancer 74 63-68.
133. Linn SC, Pinedo HM, Ark-Otte J, van d, V, Hoekman K, Honkoop AH, Vermorken JB & Giaccone G 1997 Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. International Journal of Cancer 71 787-795.
134. Liu TJ, Tsai SC, Ho YJ, Sun SS & Kao CH 2002 Comparison of the expression of P-glycoprotein, Ki-67, and P-53 to technetium-99m tetrofosmin mammoscintigraphic findings. Cancer Investigation 20 199-205.
135. Loe DW, Almquist KC, Cole SP & Deeley RG 1996a ATP-dependent 17 beta-estradiol 17-(beta-d-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. Journal of Biological Chemistry 271 9683-9689.
136. Loe DW, Almquist KC, Deeley RG & Cole SP 1996b Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. Journal of Biological Chemistry 271 9675-9682.
137. Loo TW & Clarke DM 1997 Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. Journal of Biological Chemistry 272 31945-31948.
138. Loo TW & Clarke DM 1999a Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane. Journal of Biological Chemistry 274 35388-35392.
139. Loo TW & Clarke DM 1999b Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. Biochimica et Biophysica Acta 1461 315-325.
140. Loo TW & Clarke DM 2000 Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. Journal of Biological Chemistry 275 39272-39278.
141. Loo TW & Clarke DM 2001a Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. Journal of Biological Chemistry 276 36877-36880.
142. Loo TW & Clarke DM 2001b Cross-linking of human multidrug resistance P-glycoprotein by the substrate tris-(2-maleimidoethyl)amine, is altered by ATP hydrolysis. Journal of Biological Chemistry 276 31800-31805.
143. Loo TW & Clarke DM 2002 Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site. PNAS 99 3511-3516.
144. Lorico A, Rappa G, Flavell RA & Sartorelli AC 1996 Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Research 56 5351-5355.
145. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA & Sartorelli AC 1997 Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Research 57 5238-5242.
146. Maddahi J, Kiat H & Berman DS 1991 Myocardial perfusion imaging with technetium-99m-labeled agents. American Journal of Cardiology 67 27D-34D.
147. Manciu L, Chang XB, Riordan JR & Ruysschaert JM 2000 Multidrug resistance protein MRP1 reconstituted into lipid vesicles: secondary structure and nucleotide-induced tertiary structure changes. Biochemistry 39 13026-13033.
148. Manciu L, Chang XB, Buyse F, Hou YX, Gustot A, Riordan JR & Ruysschaert JM 2003 Intermediate structural states involved in MRP1-mediated drug transport: role of glutathione. Journal of Biological Chemistry 278 3347-3356.
149. 125I]LY475776. Evidence of a major binding site in the COOH-proxymal membrane spanning domain. Journal of Biological Chemistry 277 28690-28699.
150. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ & Fruehauf JP 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to Taxol and doxorubicin. Clinical Cancer Research 4 389-398.
151. Merkel DE, Fuqua SA, Tandon AK, Hill SM, Buzdar AU & McGuire WL 1989 Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. Journal of Clinical Oncology 7 1129-1136.
152. Miller KD & Sledge GW Jr 1999 The role of chemotherapy for metastatic breast cancer. Hematology/Oncology Clinics of North America 13 415-434.
153. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T et al. 1999 Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Research 59 8-13.
154. Miyazaki M, Kohno K, Uchiumi T, Tanimura H, Matsuo K, Nasu M & Kuwano M 1992 Activation of human multidrug resistance-1 gene promoter in response to heat shock stress. Biochemical and Biophysical Research Communications 187 677-684.
155. Moll UM & Chumas J 1997 Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer. Pathology, Research and Practice 193 187-196.
156. Moretti JL, Duran Cordobes M, Starzec A, de Beco V, Vergote J, Benazzouz F, Boissier B, Cohen H, Safi N, Pipemo-Neumann S et al. 1998 Involvement of glutathione in loss of technetium-glutathione 99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. Journal of Nuclear Medicine 39 1214-1218.
157. Mross K, Bohn C, Edler L, Jonat W, Queisser W, Heidemann E, Goebel M & Hossfeld DK 1993 Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Intemistische Onkologie of the German Cancer Society. Annals of Oncology 4 45-50.
158. Mubashar M, Harrington KJ, Chaudhary KS, Lalani el-N, Stamp GW, Sinnett D, Glass DM & Peters AM 2002 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. Journal of Nuclear Medicine 43 519-525.
159. Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, de Vries EG & Jansen PL 1994 Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. PNAS 91 13033-13037.
160. Murren JR, Durivage HJ, Buzaid AC, Reiss M, Flynn SD, Carter D & Hait WN 1996 Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. Cancer Chemotherapy and Pharmacology 38 65-70.
161. Naito M, Yusa K & Tsuruo T 1989 Steroid hormones inhibit binding of vinca alkaloid to multidrug resistance related P-glycoprotein. Biochemical and Biophysical Research Communications 158 1066-1071.
162. Neyfakh AA, Serpinskaya AS, Chervonsky AV, Apasov SG & Kazarov AR 1989 Multidrug-resistance phenotype of a subpopulation of T-lymphocytes without drug selection. Experimental Cell Research 185 496-505.
163. Nooter K, de la Riviere GB, Klijn J, Stoter G & Foekens J 1997a Multidrug resistance protein in recurrent breast cancer. Lancet 349 1885-1886.
164. Nooter K, Brutel DLR, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JG, Stoter G & Foekens JA 1997b The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. British Journal of Cancer 76 486-493.
165. O'Driscoll L, Kennedy S, McDermott E, Kelehan P & Clynes M 1996 Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue. European Journal of Cancer 32A 128-133.
166. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M & Kohno K 1998 Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. Journal of Biological Chemistry 273 5997-6000.
167. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA & Croop JM 1993 Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Research 53 977-984.
168. Qian XD & Beck WT 1990 Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts. Journal of Biological Chemistry 265 18753-18756.
169. Raviv Y, Pollard HB, Bruggemann EP, Pastan I & Gottesman MM 1990 Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. Journal of Biological Chemistry 265 3975-3980.
170. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ & Korzekwa KR 1994 O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Molecular Pharmacology 45 352-358.
171. Riehm H & Biedler JL 1971 Cellular resistance to daunomycin in Chinese hamster cells in vitro. Cancer Research 31 409-412.
172. Ries F & Dicato M 1991 Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. A phase I-II clinical trial. Medical Oncology and Tumor Pharmacotherapy 8 39-43.
173. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G & Blick M 1990 Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Human Pathology 21 787-791.
174. Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE & Schneider E 2000 The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochemical and Biophysical Research Communications 271 42-46.
175. Roninson IB, Abelson HT, Housman DE, Howell N & Varshavsky A 1984 Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells. Nature 309 626-628.
176. Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM & Pastan I 1986 Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. PNAS 83 4538-4542.
177. Rosenberg MF, Callaghan R, Ford RC & Higgins CF 1997 Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. Journal of Biological Chemistry 272 10685-10694.
178. Rosenberg MF, Mao Q, Holzenburg A, Ford RC, Deeley RG & Cole SP 2001 The structure of the multidrug resistance protein 1 (MRP1/ABCC1). Crystallization and single particle analysis. Journal of Biological Chemistry 276 16076-16082.
179. Ruetz S, Brault M, Kast C, Hemenway C, Heitman J, Grant CE, Cole SP, Deeley RG & Gros P 1996 Functional expression of the multidrug resistance-associated protein in the yeast Saccharomyces cerevisiae. Journal of Biological Chemistry 271 4154-4160.
180. Salmon SE, Grogan TM, Miller T, Scheper R & Dalton WS 1989 Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. Journal of the National Cancer Institute 81 696-701.
181. Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G & Silvestrini R 1991 Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. European Journal of Cancer 27 155-158.
182. Sapunar F & Smith IE 2000 Neoadjuvant chemotherapy for breast cancer. Annals of Medicine 32 43-50.
183. Scala S, Saeki T, Lynch A, Salomon D, Merino MJ & Bates SE 1995 Coexpression of TGF alpha, epidermal growth factor receptor, and P-glycoprotein in normal and benign diseased breast tissues. Diagnostic Molecular Pathology 4 136-142.
184. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O et al. 1997 Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. PNAS 94 4028-4033.
185. Schneider J & Romero H 1995 Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients. Anticancer Research 15 1117-1121.
186. Schneider J, Gonzalez-Roces S, Pollan M, Lucas R, Tejerina A, Martin M & Alba A 2001 Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Research 3 183-191.
187. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JP, Eekman CA, Kuiper CM, Feller N, van Heijningen TH, Klumper E & Pieters R 1995 Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-d-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clinical Cancer Research 1 81-93.
188. Sedlacek SM 1990 Salvage therapy for metastatic disease. Seminars in Oncology 17 45-49.
189. Seymour L, Bezwoda WR & Dansey RD 1995 P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Research and Treatment 36 61-69.
190. Slapak CA, Fracasso PM, Martell RL, Toppmeyer DL, Lecerf JM & Levy SB 1994 Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Research 54 5607-5613.
191. Soussi T 2000 The p53 tumor suppressor gene: from molecular biology to clinical investigation. Annals of the New York Academy of Sciences 910 121-137.
192. Stein U, Rau B, Wust P, Walther W & Schlag PM 1999 Hyperthermia for treatment of rectal cancer: evaluation for induction of multidrug resistance gene (mdr1) expression. International Journal of Cancer 80 5-12.
193. Strauss BE & Haas M 1995 The region 3′ to the major transcriptional start site of the MDR 1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochemical and Biophysical Research Communications 217 333-340.
194. Strauss BE, Shivakumar C, Deb SP, Deb S & Haas M 1995 The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochemical and Biophysical Research Communications 217 825-831.
195. Sugawara I 1990 Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta Pathologica Japonica 40 545-553.
196. Sukhai M & Piquette-Miller M 2000 Regulation of the multidrug resistance genes by stress signals. Journal of Pharmacy and Pharmaceutical Sciences 3 268-280.
197. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK & Kao CH 2000 Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results. Cancer Letters 153 95-100.
198. Tansan S, Koc Y, Aydin H, Urbano G & McCaffrey R 1997 Augmentation of vincristine cytotoxicity by megestrol acetate. Cancer Chemotherapy and Pharmacology 39 333-340.
199. Takeuchi N, Fukumoto M, Nishioka A, Akagi N, Murata Y, Takeuchi S, Ogawa Y & Yoshida S 2002 Scintigraphic prediction of response to chemotherapy in patients with breast cancer: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. International Journal of Oncology 20 53-58.
200. Taylor CW, Dalton WS, Mosley K, Dorr RT & Salmon SE 1997 Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Research and Treatment 42 7-14.
201. Teicher BA 1994 Hypoxia and drug resistance. Cancer Metastasis Reviews 13 139-168.
202. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I & Willingham MC 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. PNAS 84 7735-7738.
203. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I & Willingham MC 1989 Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. Journal of Histochemistry and Cytochemistry 37 159-164.
204. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG & Schuetz JD 1997 p53-Dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. PNAS 94 11037-11042.
205. Thurlimann B, Kroger N, Greiner J, Mross K, Schuller J, Schemhammer E, Schumacher K, Gastl G, Hartlapp J, Kupper H et al. 1995 Dexverapamil to overcome epirubicin resistance in advanced breast cancer. Journal of Cancer Research and Clinical Oncology 121 (Suppl 3) R3-R6.
206. Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel R, Chang R, Noone MH, Denicoff AM, Barnes CS, Gossard MR et al. 1996 Phase I crossover study of paclitaxel with r-Verapamil in patients with metastatic breast cancer. Journal of Clinical Oncology 14 1173-1184.
207. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW et al. 2002 Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clinical Cancer Research 8 670-678.
208. Trock BJ, Leonessa F & Clarke R 1997 Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. Journal of the National Cancer Institute 89 917-931.
209. Uchiumi T, Kohno K, Tanimura H, Hidaka K, Asakuno K, Abe H, Uchida Y & Kuwano M 1993a Involvement of protein kinase in environmental stress-induced activation of human multidrug resistance 1 (MDR1) gene promoter. FEBS Letters 326 11-16.
210. Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, Uchida Y & Kuwano M 1993b Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth and Differentiation 4 147-157.
211. van der Heyden S, Gheuens E, De Bruijn E, Van Oosterom A & Maes R 1995 P-glycoprotein: clinical significance and methods of analysis. Critical Reviews in Clinical Laboratory Sciences 32 221-264.
212. van der Valk, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJ, Pinedo HM et al. 1990 Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Annals of Oncology 1 56-64.
213. van Kalken CK, van der Hoeven JJ, de Jong J, Giaccone G, Schuurhuis GJ, Maessen PA, Blokhuis WM, van der Vijgh WJ & Pinedo HM 1991 Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. European Journal of Cancer 27 739-744.
214. van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J & Giaccone G 1993 Cortisol is transported by the multidrug resistance gene product P-glycoprotein. British Journal of Cancer 67 284-289.
215. van Luyn MJ, Muller M, Renes J, Meijer C, Scheper RJ, Nienhuis EF, Mulder NH, Jansen PL & de Vries EG 1998 Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1. International Journal of Cancer 76 55-62.
216. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT & Ciocca DR 1999 c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. International Journal of Cancer 84 129-134.
217. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R & Silvestrini R 1994 Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. European Journal of Cancer 30A 1002-1007.
218. Vergote J, Moretti JL, de Vries EG & Gamier-Suillerot A 1998 Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. European Journal of Biochemistry 252 140-146.
219. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R & Chassagne J 1991 Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. Journal of the National Cancer Institute 83 111-116.
220. Wackers FJ, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, Boucher CA, Picard M, Holman BL & Fridrich R 1989 Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. Journal of Nuclear Medicine 30 301-311.
221. Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H & Pirker R 1991 MDR1 gene expression and prognostic factors in primary breast carcinomas. European Journal of Cancer 27 1352-1355.
222. Wang CS, LaRue H, Fortin A, Gariepy G & Tetu B 1997 mdr1 MRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Research and Treatment 45 63-74.
223. Warner E, Hedley D, Andrulis I, Myers R, Trudeau M, Warr D, pritchard KI, Blackstein M, Goss PE, Franssen E et al. 1998 Phase II study of dexverapamil plus anthracycline in patients ith metastatic breast cancer who have progressed on the same anthracycline regimen. Clinical Cancer Research 4 1451-1457.
224. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van d, V, Krimpenfort P & Borst P 1997 Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Medicine 3 1275-1279.
225. Wijnholds J, Scheffer GL, van d, V, van d, V, Beijnen JH, Scheper RJ & Borst P 1998 Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. Journal of Experimental Medicine 188 797-808.
226. Wijnholds J, deLange EC, Scheffer GL, van den Berg DJ, Mol CA, van der Valk P, Schinkel AH, Scheper RJ, Breimer DD & Borst P 2000 Multidrug resistance protein I protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. Journal of Clinical Investigation 105 279-285.
227. Winer EP, Morrow M, Osborne CK & Harris JR 2001 In Cancer: Principles and Practice of Oncology, edn 6. Eds VT De Vita Jr, S Hellman & SA Rosenberg. Philadelphia: Lippincott Williams and Wilkins.
228. Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS, Tsuruo T & Kaye SB 1990 P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. British Journal of Cancer 62 758-761.
229. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RC et al. 1994 Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. Journal of Clinical Oncology 12 1771-1777.
230. Wolf DC & Horwitz SB 1992 P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. International Journal of Cancer 52 141-146.
231. Yang CP, DePinho SG, Greenberger LM, Arceci RJ & Horwitz SB 1989 Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. Journal of Biological Chemistry 264 782-788.
232. Yang CP, Shen HJ & Horwitz SB 1994 Modulation of the function of P-glycoprotein by estramustine. Journal of the National Cancer Institute 86 723-725.
233. Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F & Press MF 1999 MDR1 gene expression in primary and advanced breast cancer. Laboratory Investigation 79 271-280.
234. Yao D, Ding S, Burchell B, Wolf CR & Friedberg T 2000 Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. Journal of Pharmacology and Experimental Therapeutics 294 387-395.
235. Yoon JH, Bom HS, Song HC, Lee JH & Jaegal YJ 1999 Double-phase Tc-99m sestamibi scintimammography to assess angiogenesis and P-glycoprotein expression in patients with untreated breast cancer. Clinical Nuclear Medicine 24 314-318.
236. Zalcberg JR, Hu XF, Ching M, Wakeling A, Wall DM, Marschner IC & De Luise M 1993 Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines. Cancer Chemotherapy and Pharmacology 33 123-129.
237. Zaman GJ, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ et al. 1994 The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. PNAS 91 8822-8826.
238. Zhou G & Kuo MT 1998 Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. Journal of Biological Chemistry 273 15387-15394.
239. Zochbauer-Muller S, Filipits M, Rudas M, Brunner R, Krajnik G, Suchomel R, Schmid K & Pirker R 2001 P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Anticancer Research 21 119-124.